₹9.55
(Market cap
₹2,815 Cr
Recently Viewed
Clear AllMarket cap
₹2,815 Cr
Revenue (TTM)
₹811 Cr
P/E Ratio
149.2
P/B Ratio
2.2
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹19 Cr
ROE
7.9 %
ROCE
8 %
Industry P/E
35.53
EV/EBITDA
39.8
Debt to Equity
0.1
Book Value
₹248.8
EPS
₹5.2
Face value
10
Shares outstanding
50,719,105
CFO
₹910.82 Cr
EBITDA
₹711.52 Cr
Net Profit
₹-1,028.73 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Orchid Pharma
| -26.9 | 4.2 | -20.8 | -28.5 | 12.5 | -17.3 | 29.7 |
|
BSE Healthcare
| 0.0 | 2.7 | 4.4 | 4.2 | 24.0 | 13.2 | 10.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Orchid Pharma
| -58.7 | 147.8 | 95.7 | -7.8 | 205.2 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Orchid Pharma
|
554.9 | 2,815.2 | 811.2 | 17.4 | 0.8 | 2.1 | 149.2 | 2.2 |
| 361.6 | 3,299.0 | 2,521.8 | 202.5 | 9.6 | 14.3 | 16.3 | 2.2 | |
| 1,073.2 | 13,168.4 | 2,512.3 | 543.7 | 28.3 | 19.3 | 24.2 | 4.2 | |
| 415.3 | 7,210.1 | 1,053.1 | 293.6 | 32.3 | 24.6 | 24.6 | 5.6 | |
| 1,043.7 | 10,951.2 | 1,158.7 | 309.6 | 31.9 | 17.3 | 35 | 5.8 | |
| 1,592.7 | 30,187.4 | 8,850.1 | 894.8 | 15.2 | 19.8 | 34.7 | 6.1 | |
| 330.8 | 3,600.2 | 159.3 | 47.8 | 39.0 | 18.6 | 75.3 | 13.0 | |
| 14,920.0 | 19,156.9 | 1,575.1 | 179.1 | 14.9 | 11.4 | 106.9 | 11.5 | |
| 895.7 | 4,131.5 | 588.5 | 102.9 | 22.1 | 12.7 | 40.7 | 4.9 | |
| 210.5 | 5,521.0 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 8.3 |
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical... ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited. Read more
Incorporated
1992
Chairman
Ram Gopal Agarwal
Managing Director
Manish Dhanuka
Headquarters
Chengalpattu, Tamil Nadu
Website
Looking for more details about Orchid Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsIntimation Under Regulation 30
11-Apr-2026No News & Announcements are available.
The share price of Orchid Pharma Ltd is ₹554.85 (NSE) and ₹555.05 (BSE) as of 21-Apr-2026 IST. Orchid Pharma Ltd has given a return of 12.54% in the last 3 years.
The P/E ratio of Orchid Pharma Ltd is 149.21 times as on 21-Apr-2026, a 320 premium to its peers’ median range of 35.53 times.
The P/B ratio of Orchid Pharma Ltd is 2.23 times as on 21-Apr-2026, a 1 premium to its peers’ median range of 2.21 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
39.54
|
3.11
|
|
2024
|
57.52
|
4.53
|
|
2023
|
33.87
|
2.28
|
|
2022
|
0.00
|
1.79
|
|
2021
|
0.00
|
15.41
|
The 52-week high and low of Orchid Pharma Ltd are Rs 899.00 and Rs 480.00 as of 21-Apr-2026.
Orchid Pharma Ltd has a market capitalisation of ₹ 2,815 Cr as on 21-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Orchid Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.